



ATTORNEY DOCKET NO. 26007.0003U2  
PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:	)	
	)	
Rubinstein <i>et al.</i>	)	Group Art Unit: 1632
	)	
Application No. 10/730,209	)	Examiner: Unassigned
	)	
Filed: December 8 2003	)	Confirmation No.: 4631
	)	
Title: TRANSGENIC ZEBRAFISH MODELS	)	
FOR ANGIOGENESIS	)	

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.  
Customer Number 23859

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Form PTO 1449 is a listing of documents known to Applicants and/or their attorneys. A copy of each of these documents is enclosed.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(b)(3), in that a first Office Action on the merits of the present patent application has not yet been mailed to Applicants.


Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

**ATTORNEY DOCKET NO. 26007.0003U2**  
**Application No. 10/730,209**


No fee is believed due; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.


Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

  
Lizette M. Fernandez  
Reg. No. 49,694

NEEDLE & ROSENBERG, P.C.  
Customer Number 23859  
(678) 420-9300  
(678) 420-9301 (fax)

<u>CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8</u>	
I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.	
 Lizette M. Fernandez	Date <u>8/30/04</u>



Form P-100 (Rev. 10-2003)		Complete if Known	
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Application Number	10/730,209
		Confirmation No.	4631
		Filing Date	December 8, 2003
LIST OF INFORMATION CITED BY APPLICANT (Use as many sheets as necessary)		First Named Inventor	Rubinstein et al.
		Group Art Unit	1632
		Examiner Name	Unassigned
<b>NON-PATENT DOCUMENTS</b>			
Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)	
MN	A1	Auerbach et al. (2000). Angiogenesis assays: problems and pitfalls. <i>Canc. Metast. Rev.</i> 19, 167-172.	
	A2	Beckwith et al. (2000). Ethylnitrosourea induces neoplasia in zebrafish ( <i>Danio rerio</i> ). <i>Lab Invest.</i> 80, 379-85.	
	A3	Chan et al. (2002). Dissection of angiogenic signaling in zebrafish using a chemical genetic approach. <i>Cancer Cell</i> 1, 257-267.	
	A4	Childs et al. (2002). Patterning of angiogenesis in the zebrafish embryo. <i>Development</i> 129, 973-982.	
	A5	Fong, et al. (1999). SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. <i>Cancer Res.</i> 59, 99-106.	
	A6	Fouquet et al. (1997). Vessel patterning in the embryo of the zebrafish: guidance by notochord. <i>Dev. Biol.</i> 183, 37-48.	
	A7	Gale & Yancopoulos, (1999). Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. <i>Genes Dev.</i> 13, 1055-1066.	
	A8	Habeck et al. 2000 screen consortium. (2002). Analysis of a zebrafish VEGF receptor mutant reveals specific disruption of angiogenesis. <i>Curr Biol.</i> 12, 1405-1412.	
	A9	Hanahan, D. & Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. <i>Cell</i> 86, 353-364.	
	A10	Isogai et al. (2001). The vascular anatomy of the developing zebrafish: an atlas of embryonic and early larval development. <i>Dev. Biol.</i> 230, 278-301.	
	A11	Jain et al. (1997). Quantitative angiogenesis assays: Progress and problems. <i>Nat. Med.</i> 3, 1203-1208.	
	A12	Laird et al. (2000). SU6668 is a potent anti-angiogenic and antitumor agent that induces regression of established tumors. <i>Cancer Res.</i> 60, 4152-4160.	
	A13	Lawson & Weinstein, (2002). <i>In vivo</i> imaging of embryonic vascular development using transgenic zebrafish. <i>Dev. Biol.</i> 248, 307-318.	
	A14	Li et al. (2000). Role of incipient angiogenesis in cancer metastasis. <i>Cancer Met. Rev.</i> 19, 7-11.	
	A15	Liao, et al. The zebrafish gene cloche acts upstream of a flk-1 homologue to regulate endothelial cell differentiation. <i>Development</i> 124, 381-389 (1997).	
	A16	Matz, et al. (2000). Fluorescent proteins from nonbioluminescent Anthozoa species. <i>Nat. Biotech.</i> 17, 969-973.	
	A17	Mendel et al. (2000a). Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. <i>Anti-Cancer Drug Des.</i> 15, 29-41.	
	A18	Mendel, et al. (2000b). The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. <i>Clin. Canc. Res.</i> 6, 4848-4858.	
MN	A19	Motoike, et al. (2000). Universal GFP reporter for the study of vascular development. <i>Genesis</i> 28, 75-81.	

/Marcia Noble/

01/27/2007

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Complete if Known	
LIST OF INFORMATION CITED BY APPLICANT (Use as many sheets as necessary)		Application Number	10/730,209
		Confirmation No.	4631
		Filing Date	December 8, 2003
		First Named Inventor	Rubinstein et al.
		Group Art Unit	1632
		Examiner Name	Unassigned

MN	A20	Nasevicius & Ekker (2000). Effective targeted gene 'knockdown' in zebrafish. <i>Nat Genet.</i> 26, 216-20.
	A21	Nasevicius et al. (2000). Distinct requirements for zebrafish angiogenesis revealed by a VEGF-A morphant. <i>Yeast</i> 17, 294-301.
	A22	Padilla and Roth (2001). Oxygen deprivation causes suspended animation in the zebrafish embryo. <i>Proc. Natl. Acad. Sci. USA</i> 98, 7331-7335.
	A23	Peterson et al. (2000). Small molecule developmental screens reveal the logic and timing of vertebrate development. <i>Proc. Natl. Acad. Sci. USA</i> 97, 12965-12969.
	A24	Rosen, (2000). Anti-angiogenic strategies and agents in clinical trials. <i>Oncologist</i> 5(suppl.1), 20-27.
	A25	Shaheen et al. (1999). Anti-angiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. <i>Cancer Res.</i> 59, 5412-5416.
	A26	Shalaby et al. (1995). Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. <i>Nature.</i> 376, 62-66.
	A27	Spitsbergen et al. (2000). Neoplasia in zebrafish ( <i>Danio rerio</i> ) treated with 7,12-dimethylbenz[a]anthracene by two exposure routes at different developmental stages. <i>Toxicol Pathol.</i> 28, 705-15.
	A28	Thisse et al. (1993). Structure of the zebrafish snail1 gene and its expression in wild-type, <i>spadetail</i> and <i>no tail</i> mutant embryos. <i>Development</i> 119, 1203-1215.
	A29	Thompson et al. (1998). The cloche and spadetail genes differentially affect hematopoiesis and vasculogenesis. <i>Dev. Biol.</i> 197, 248-269.
	A30	Urtishak et al. (2003). Targeted gene knockdown in zebrafish using negatively charged peptide nucleic acid mimics. <i>Dev Dyn.</i> 228, 405-413.
	A31	Vogel & Weinstein, (2000). Studying vascular development in the zebrafish. <i>Trends Cardiovasc. Med.</i> 10, 352-360.
MN	A32	Weinstein et al. (1996). Gridlock, a localized heritable vascular patterning defect in the zebrafish. <i>Nat. Med.</i> 1, 1143-1147.

Examiner Signature: /Marcia Noble/	Date Considered: 01/27/2007
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Marcia S.  
Noble

Digitally signed by Marcia S. Noble  
DN: cn=Marcia S. Noble, c=US,  
o=USPTO, ou=AU 1632,  
email=Marcia.Noble@uspto.gov  
Date: 2007.01.27 23:27:17 -05'00'